Literature DB >> 31243811

Poorly differentiated chordoma: review of 53 cases.

H Gokce Yeter1, Kemal Kosemehmetoglu1, Figen Soylemezoglu1.   

Abstract

Poorly differentiated chordoma (PDC) is a newly described variant of chordomas, which is not considered as a subtype yet, but has its own distinct features in terms of morphology, immunohistochemical and molecular characteristics, and clinical outcome. To provide a brief review of clinical, morphological, immunohistochemical, and molecular features of poorly differentiated chordoma. PubMed search using keyword 'poorly differentiated chordoma'. A critical review of all studies with a total of 53 cases using inclusion criteria of involvement of axial skeleton (vertebra and clivus), INI1 loss (either with the aid of immunohistochemistry or various molecular techniques), and immunohistochemical brachyury expression. PDC is characterized by a young population with slight female predominance, clivus/cervix location, multinodular sheets of epithelioid cells with eosinophilic cytoplasm and prominent pleomorphism, and loss of SMARCB1/INI1 expression, which can be demonstrated both with immunohistochemical and molecular studies, and is unexpected for other types of chordoma. However, classical chordomas lacking SMARCB1/INI1 expression were also reported and how to classify these cases has not been addressed yet. This unique entity is a candidate to be recognized and distinguished from other types of chordoma or SMARCB1-deficient tumors which are clinically important differential diagnoses that represent a challenging task for the pathologists.
© 2019 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Bone and soft tissue pathology; INI1; SMARCB1; brachyury; chordoma; neuropathology

Mesh:

Year:  2019        PMID: 31243811     DOI: 10.1111/apm.12978

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  7 in total

1.  Imaging of spinal chordoma and benign notochordal cell tumor (BNCT) with radiologic pathologic correlation.

Authors:  Mark D Murphey; Matthew J Minn; Alejandro Luiña Contreras; Kelly K Koeller; Robert Y Shih; Carrie Y Inwards; Takehiko Yamaguchi
Journal:  Skeletal Radiol       Date:  2022-09-05       Impact factor: 2.128

2.  Clinicopathological and Prognostic Characteristics in Dedifferentiated/Poorly Differentiated Chordomas: A Pooled Analysis of Individual Patient Data From 58 Studies and Comparison With Conventional Chordomas.

Authors:  Fu-Sheng Liu; Bo-Wen Zheng; Tao-Lan Zhang; Jing Li; Guo-Hua Lv; Yi-Guo Yan; Wei Huang; Ming-Xiang Zou
Journal:  Front Oncol       Date:  2021-08-13       Impact factor: 6.244

3.  Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury.

Authors:  Laura M Williamson; Craig M Rive; Daniela Di Francesco; Emma Titmuss; Hye-Jung E Chun; Scott D Brown; Katy Milne; Erin Pleasance; Anna F Lee; Stephen Yip; Daniel G Rosenbaum; Martin Hasselblatt; Pascal D Johann; Marcel Kool; Melissa Harvey; David Dix; Daniel J Renouf; Robert A Holt; Brad H Nelson; Martin Hirst; Steven J M Jones; Janessa Laskin; Shahrad R Rassekh; Rebecca J Deyell; Marco A Marra
Journal:  NPJ Precis Oncol       Date:  2021-12-20

4.  Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5.

Authors:  Mingxuan Li; Yutao Shen; Yujia Xiong; Shuai Wang; Chuzhong Li; Jiwei Bai; Yazhuo Zhang
Journal:  Cell Prolif       Date:  2021-10-20       Impact factor: 6.831

5.  Research hotspots and trends of chordoma: A bibliometric analysis.

Authors:  Jianxuan Gao; Runzhi Huang; Huabin Yin; Dianwen Song; Tong Meng
Journal:  Front Oncol       Date:  2022-09-16       Impact factor: 5.738

6.  Poorly differentiated chordoma with whole-genome doubling evolving from a SMARCB1-deficient conventional chordoma: A case report.

Authors:  Christian Curcio; Robert Cimera; Ruth Aryeequaye; Mamta Rao; Nicola Fabbri; Yanming Zhang; Meera Hameed
Journal:  Genes Chromosomes Cancer       Date:  2020-10-07       Impact factor: 5.006

7.  Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft.

Authors:  Thibault Passeri; Ahmed Dahmani; Julien Masliah-Planchon; Adnan Naguez; Marine Michou; Rania El Botty; Sophie Vacher; Rachida Bouarich; André Nicolas; Marc Polivka; Coralie Franck; Anne Schnitzler; Fariba Némati; Sergio Roman-Roman; Franck Bourdeaut; Homa Adle-Biassette; Hamid Mammar; Sébastien Froelich; Ivan Bièche; Didier Decaudin
Journal:  Cancers (Basel)       Date:  2022-03-14       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.